These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24556719)

  • 1. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.
    von Scheidt B; Leung PS; Yong MC; Zhang Y; Towne JE; Smyth MJ; Teng MW
    Cancer Res; 2014 May; 74(9):2412-21. PubMed ID: 24556719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.
    Teng MW; von Scheidt B; Duret H; Towne JE; Smyth MJ
    Cancer Res; 2011 Mar; 71(6):2077-86. PubMed ID: 21282337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
    Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
    Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-VEGF antibody enhances the antitumor effect of CD40.
    Selvaraj S; Raundhal M; Patidar A; Saha B
    Int J Cancer; 2014 Oct; 135(8):1983-8. PubMed ID: 24604357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2D function protects the host from tumor initiation.
    Smyth MJ; Swann J; Cretney E; Zerafa N; Yokoyama WM; Hayakawa Y
    J Exp Med; 2005 Sep; 202(5):583-8. PubMed ID: 16129707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
    Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
    Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
    Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
    Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
    Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
    J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
    Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
    Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases.
    Hirschowitz EA; Crystal RG
    Am J Respir Cell Mol Biol; 1999 May; 20(5):935-41. PubMed ID: 10226063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
    Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE
    Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
    Jin GH; Hirano T; Murakami M
    Int Immunol; 2008 Jun; 20(6):783-9. PubMed ID: 18448458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the endogenous production of interleukin 12 in immunotherapy.
    Harada M; Tamada K; Abe K; Yasumoto K; Kimura G; Nomoto K
    Cancer Res; 1998 Jul; 58(14):3073-7. PubMed ID: 9679973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.